RT Journal Article
T1 Mitochondrial DNA Copy-Number Variation and Pancreatic Cancer Risk in the Prospective EPIC Cohort.
A1 Gentiluomo, Manuel
A1 Katzke, Verena A
A1 Kaaks, Rudolf
A1 Tjønneland, Anne
A1 Severi, Gianluca
A1 Perduca, Vittorio
A1 Boutron-Ruault, Marie-Christine
A1 Weiderpass, Elisabete
A1 Ferrari, Pietro
A1 Johnson, Theron
A1 Schulze, Matthias B
A1 Bergmann, Manuela
A1 Trichopoulou, Antonia
A1 Karakatsani, Anna
A1 La Vecchia, Carlo
A1 Palli, Domenico
A1 Grioni, Sara
A1 Panico, Salvatore
A1 Tumino, Rosario
A1 Sacerdote, Carlotta
A1 Bueno-de-Mesquita, Bas
A1 Vermeulen, Roel
A1 Sandanger, Torkjel M
A1 Quiros, J Ramon
A1 Rodriguez-Barranco, Miguel
A1 Amiano, Pilar
A1 Colorado-Yohar, Sandra
A1 Ardanaz, Eva
A1 Sund, Malin
A1 Khaw, Kay-Tee
A1 Wareham, Nicholas J
A1 Schmidt, Julie A
A1 Jakszyn, Paula
A1 Morelli, Luca
A1 Canzian, Federico
A1 Campa, Daniele
AB Mitochondrial DNA (mtDNA) copy number in peripheral blood has been found to be associated with risk of developing several cancers. However, data on pancreatic ductal adenocarcinoma (PDAC) are very limited. To further our knowledge on this topic, we measured relative mtDNA copy number by a quantitative real-time PCR assay in peripheral leukocyte samples of 476 PDAC cases and 357 controls nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. We observed lower mtDNA copy number with advancing age (P = 6.54 × 10-5) and with a high body mass index (BMI) level (P = 0.004) and no association with sex, smoking behavior, and alcohol consumption. We found an association between increased mtDNA copy number and decreased risk of developing PDAC with an odds ratios (OR) of 0.35 [95% confidence interval (CI), 0.16-0.79; P = 0.01] when comparing the fifth quintile with the first using an unconditional logistic regression and an OR of 0.19 (95% CI, 0.07-0.52; P = 0.001) with a conditional analysis. Analyses stratified by BMI showed an association between high mtDNA copy number and decreased risk in the stratum of normal weight, consistent with the main analyses. Our results suggest a protective effect of a higher number of mitochondria, measured in peripheral blood leukocytes, on PDAC risk. Our findings highlight the importance of understanding the mitochondrial biology in pancreatic cancer.
PB American Association for Cancer Research
YR 2020
FD 2020-01-07
LK http://hdl.handle.net/10668/14952
UL http://hdl.handle.net/10668/14952
LA en
NO Gentiluomo M, Katzke VA, Kaaks R, Tjønneland A, Severi G, Perduca V, et al. Mitochondrial DNA Copy-Number Variation and Pancreatic Cancer Risk in the Prospective EPIC Cohort. Cancer Epidemiol Biomarkers Prev. 2020 Mar;29(3):681-686.
NO We thank the National Institute for Public Health and the Environment (RIVM),Bilthoven, the Netherlands, for their contribution and ongoing support to the EPICStudy. This work was partially supported by intramural funds of University of Pisaand DKFZ, by Fondazione Tizzi, and by Fondazione Arpa (www.fondazionearpa.it).The EPIC-Potsdam study was funded by the Federal Ministry of Education andResearch (Germany), the German Cancer Aid, the German Cancer Research Center,and the German Institute of Human Nutrition Potsdam-Rehbr€ucke. EPIC-Oxfordwas supported by Cancer Research UK (C8221/A19170) and the Medical ResearchCouncil UK (MR/M012190/1). EPIC-Greece was supported by the Hellenic HealthFoundation.
DS RISalud
RD Apr 5, 2025